Most billing companies code per block. Medicare pays per specimen. That mismatch costs your pathology lab 8-15% of surgical pathology revenue annually. Medivantek's pathology specialists code 88305 per specimen, attach MolDX z-codes to every molecular test, and never miss modifier 90 for reference lab testing.
Request Free Pathology Revenue Audit
Pathology is not radiology. It is not emergency medicine. It is not laboratory testing in the traditional sense. And yet, most medical billing companies apply the same workflows to your pathology claims as they do to a routine CBC.
That mismatch costs your practice between 8–15% of collectible revenue annually — not because the tests weren't performed, but because the billing lacked pathology-specific logic.
At Medivantek medical billing services, we separate your revenue cycle into three distinct workstreams: anatomic pathology (surgical specimens, biopsies, cytology, autopsies), clinical pathology (blood, urine, chemistry, hematology), and molecular pathology (81200–81471, including MolDX compliance).
Each workstream has its own coders, its own modifier rules, and its own denial workflows.
The most common pathology billing error is also the most expensive: unbundling. A general biller sees a requisition form with five line items. They code five units of 88305. You get paid for five blocks. Then Medicare audits you 18 months later and recoups everything — because those five blocks came from a single specimen.
How we prevent this: Our coders read the gross description. We count specimens, not containers, not blocks. One breast lumpectomy specimen = one 88305, regardless of whether the pathologist took ten blocks. Ten separate biopsies from ten distinct anatomic sites = ten units of 88305.
What this means for your practice: Compliance with CMS Correct Coding Initiative (CCI) edits. No audit exposure. No recoupments. And revenue that reflects the work actually performed.
Pathology modifiers are non-negotiable. Miss one, and your claim is either denied or — worse — paid incorrectly, setting up a future audit.
What this means for your practice: Modifier accuracy that survives payer audits. No revenue left behind on reference lab testing. No compliance penalties.
Molecular pathology is the fastest-growing segment of pathology revenue — and the fastest-growing source of denials. Payers, including Medicare, now require MolDX z-codes for most molecular tests (81200–81389, 81400–81471). A z-code is not optional. It is not a suggestion. It is a payment requirement.
Our molecular workflow:
| Denial Reason | Frequency In General Billing | Medivantek Approach | Expected Recovery |
|---|---|---|---|
| Unbundled 88305 (Per Block Billing) | 25% Of Surgical Pathology Claims | Per-Specimen Coding With Gross Review | 99% Prevention |
| Missing Modifier 90 (Reference Lab) | 18% Of Send-Out Claims | Automated Flagging + CLIA Attachment | 98% Capture |
| Missing Z-Code (Molecular) | 35% Of Molecular Claims | Integrated Z-Code Library | 100% Capture Before Submission |
| No Clinical Utility Documentation | 20% Of Molecular Denials | Peer-Reviewed Literature Per Analyte | 75% Appeal Success |
| Modifier 26/TC Mismatch | 12% Of Split-Component Claims | One-Time Practice Mapping | 99% Accuracy |
| Pathology Code | Handled Correctly |
|---|---|
| Surgical Pathology (88300–88309) | Per Specimen, Not Per Block |
| Molecular Pathology (81200–81471) | Z-Code Attached To Every Claim |
| Cytology (88104–88199) | Pap, FNA, Fluid Specimens |
| Clinical Pathology (80047–89398) | Chemistry, Hematology, Toxicology |
| Flow Cytometry (88184–88189) | Immunophenotyping For Hematologic Malignancies |
| Cytogenetic Studies (88230–88299) | Chromosome Analysis For Oncology |
| Immunohistochemistry (88342–88344) | Per Antibody, Per Specimen |
| Gross Examination (88300) | Simple Specimens With No Microscopic |
We verify coverage before every procedure. Screening frequency. Diagnostic benefits. Prior authorization requirements. Visit limits. Patient cost-sharing. No surprises on the day of service.
We submit authorization requests within 24 hours of scheduling. We track approvals, effective dates, and expiration dates. We re-verify before every claim.
We capture every charge from the procedure note. Colonoscopy. EGD. Biopsy. Polyp removal. Pathology Infusion. No missed codes. No lost revenue.
We scrub every claim against GI-specific NCCI edits, payer policies, and Medicare LCDs. Wrong modifiers. Missing add-ons. Incorrect POS codes. We catch them before the claim goes out.
We work on every denial within 48 hours. We appeal with payer-specific arguments. We track denial patterns by payer and by code. We fix root causes, not just individual claims.
We follow up on every unpaid claim at 15, 30, 45, and 60 days. We reconcile payments against contracted rates. We appeal underpayments. We keep your AR days low.
You own the equipment and employ the pathologists. Bill globally (no modifier) or split 26/TC based on your contracting model.
You order the test. Another lab performs it. Modifier 90 is required. We attach it automatically with the reference lab's CLIA number.
If your lab owns the equipment but a separate entity interprets — Modifier TC for you, modifier 26 for the pathologist. We map your model once. Every claim thereafter is correct.
Skin pathology is high-volume and high-risk. Multiple biopsies from one patient = multiple 88305 codes if from distinct anatomic sites. Multiple blocks from one biopsy = one 88305. We read the gross description. We get it right.
Requires documentation of gross examination
No separate payment for block preparation.
Most Medicare contractors require z-codes for 81200–81471. No z-code = no payment.
Modifier 90 + referring lab's CLIA number + documentation that your practice ordered the test.
Reference labs have shorter filing windows. We track and submit before deadlines.
Our pathology unit handles over 15,800 pathology claims monthly across independent labs, hospital outreach programs, and university-affiliated pathology groups.
Our team maintains a current z-code library covering all major molecular tests, updated quarterly with payer policy changes.
Per-specimen coding, proper modifier use, and documented clinical utility mean your claims survive payer scrutiny.